相关临床试验
69
41 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1930
进行中（未招募）
3
4.3%
已完成
18
26.1%
尚未招募
38
55.1%
招募中
8
11.6%
Unknown
2
2.9%
暂无批准数据
- Duke University researchers developed Raygun, an AI framework that can resize proteins—making them shorter or longer—while preserving their structure and function, published in Nature. - Raygun builds on protein language models like ESM-2, converting proteins into standardized mathematical representations to enable extensive modifications without disrupting structural integrity. - The tool requires only two user settings: one controlling how much the protein sequence changes and another determining whether the protein becomes shorter or longer. - Experts describe Raygun as a meaningful first step toward editing existing proteins for biotechnology applications, including the development of targeted medicines.
- Duke University researchers discovered that G protein-coupled receptors (GPCRs), targets of roughly one-third of FDA-approved drugs, signal through liquid-like protein clusters called biomolecular condensates formed by β-arrestin proteins. - The findings, published in Nature, reveal an unexpected mechanism that could enable more precise control of GPCR activity and open new avenues for drug development. - When scientists disrupted the condensates, GPCR signaling was disrupted, demonstrating that β-arrestin clustering directly influences how these critical receptors function. - The study builds on Duke's legacy in GPCR research, including Nobel laureate Robert Lefkowitz's discoveries, and suggests condensates may offer ways to target specific signaling pathways while avoiding others.
- Many patients with rheumatoid arthritis and other immune-mediated inflammatory diseases fail to meet treatment goals despite biologic therapy, giving rise to a "difficult-to-treat" population that requires holistic care. - Psychosocial distress, comorbidities, chronic pain syndromes, and system-related barriers — not just pharmacotherapeutic failure — drive poor outcomes in difficult-to-treat patients, according to viewpoint articles in Nature Reviews Rheumatology and Lancet Rheumatology. - Experts emphasize that rheumatologists must look beyond disease activity scores, incorporating multidisciplinary care, lifestyle medicine, and patient-centered communication to address the full complexity of these cases. - Leading rheumatologists call on organizations like the ACR and EULAR to expand clinical guidelines, fund research into non-pharmacologic therapies, and codify whole-person care models for this underserved population.
- Duke researchers identified three drug-like molecules that directly bind β-arrestins and block their interaction with GPCRs without affecting G protein signaling. - Cryo-EM revealed one compound, Cmpd-5, binds a previously unknown allosteric pocket on β-arrestin, changing its shape globally to prevent GPCR engagement. - The inhibitors worked even when the GLP-1 receptor was stimulated by weight-loss drugs Ozempic and Wegovy, prolonging G protein signaling. - The discovery provides the first chemical tools for studying β-arrestin biology and suggests a path toward more precise therapies for metabolic, immune, cardiovascular, and neurological conditions.
- CN-105, an experimental apolipoprotein E mimetic peptide developed at Duke University, demonstrated safety and tolerability in a phase 2 clinical trial involving 186 older surgical patients. - The drug showed a promising trend toward reducing postoperative delirium, with 19.3% of CN-105 patients experiencing delirium compared to 26.5% in the placebo group, representing an approximate 25% relative risk reduction. - Patients receiving CN-105 had fewer overall complications, with a median of one moderate or serious complication versus two in the placebo group. - The results support advancing to a larger phase 3 trial to definitively assess CN-105's effectiveness in preventing postoperative delirium, a condition affecting one in four older patients and costing the U.S. healthcare system $80 billion annually.
- A landmark clinical trial involving 1,658 participants across six U.S. academic centers found that a structured behavioral hydration program using smart bottles and coaching failed to significantly reduce kidney stone recurrence rates. - Despite participants modestly increasing their urine output through the intervention, the improvement was insufficient to prevent symptomatic stone recurrence compared to standard care over the two-year study period. - The findings highlight the significant challenge patients face in maintaining the high fluid intake necessary for kidney stone prevention, even with technological support and financial incentives. - Researchers suggest the need for more personalized approaches to kidney stone prevention, as a single hydration target may not work for all patients due to varying individual factors.
- Io Therapeutics presented preclinical data at ASH 2025 showing their RXR agonist IRX4204 enhances BCMA CAR-T cell persistence and anti-tumor function in multiple myeloma models. - The compound protects CAR-T cells from ferroptosis-mediated cell death while simultaneously inducing ferroptosis in myeloma cells through distinct molecular mechanisms. - IRX4204 demonstrated synergistic efficacy when combined with both BCMA CAR-T cells and lenalidomide, significantly improving tumor control and survival in xenograft models. - Bioinformatic analysis revealed high HMOX1 expression correlates with improved overall survival in multiple myeloma patients (HR=0.51, p<0.001), suggesting potential for biomarker-guided therapy.
- The World Health Organization's International Nonproprietary Names Expert Committee approved "liraltagene autoleucel" as the official name for Anixa Biosciences' FSHR-targeted CAR-T therapy for recurrent ovarian cancer. - The therapy represents a novel CER-T (chimeric endocrine receptor-T cell) technology that uses the natural FSH ligand instead of antibody fragments to target the FSHR receptor on tumor cells. - Anixa is currently conducting a Phase 1 first-in-human trial in partnership with Moffitt Cancer Center, with plans to commence the 5th dose cohort in the coming weeks. - The INN approval marks a significant regulatory milestone toward potential global commercialization of this innovative immunotherapy approach for ovarian cancer treatment.
- The FDA has issued a safety communication warning healthcare providers about serious complications from radiofrequency microneedling devices, including thermal burns, scarring, fat loss, and nerve damage. - These Class II medical devices, designed for skin rejuvenation and wrinkle reduction, have been associated with adverse events requiring surgical intervention or additional medical treatment. - The agency emphasizes that RF microneedling is a medical procedure requiring trained healthcare professionals, not a cosmetic treatment for home use. - Healthcare providers are advised to carefully assess treatment parameters, educate patients about risks, and report adverse events through the FDA's MedWatch system.
- A gene therapy for ADA-SCID achieved a 95% success rate, completely restoring immune function in 59 of 62 children treated between 2012 and 2019. - The treatment uses patients' own stem cells modified with a healthy ADA gene, eliminating the need for immunosuppressive drugs required with bone marrow transplants. - Long-term follow-up data spanning 474 patient-years shows stable immune function with no severe complications, with some patients now living normal lives over a decade post-treatment. - The therapy is being prepared for FDA approval and could become the new standard of care for this ultra-rare disease affecting fewer than 10 U.S. children annually.
